Par, Mylan launch generic Tambocor
Executive SummaryPar has launched a generic version of 3M's antiarrhythmic Tambocor (flecainide) and has received marketing exclusivity (1"The Pink Sheet" May 6, In Brief). Mylan has also begun shipments of generic Tambocor after licensing the product from 3M...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.